Omnicell price target lowered to $30 from $37 at BofA

BofA analyst Allen Lutz lowered the firm’s price target on Omnicell (OMCL) to $30 from $37 and keeps a Neutral rating on the shares. Omnicell has executed well over the last few quarters, which gives the firm incremental confidence about the potential to stabilize product revenue, but significant tariff impacts create uncertainty on the bottom line, the analyst tells investors in a post-earnings note. The firm raised its FY25 revenue estimate to $1.138B following Q1 outperformance, but lowered its FY25 EBITDA estimate to $105.2M to account for a $40M mitigated tariff impact and slightly higher SG&A spending, BofA noted.